It can be very challenging to treat cancer that comes back after initial treatment. When multiple myeloma returns after remission, it’s referred to as a relapse. Many multiple myeloma patients relapse ...

So access and cost for these new treatments is a unique challenge, such that several groups have now shown that as patients get more and more relapse ... the paradigm in myeloma has been, this ...

Bone pain, osteoporosis, fatigue, kidney trouble, anemia, elevated blood calcium levels (hypercalcemia), a weakened immune system and increased bleeding are the most common symptoms of multiple ...

Anitocabtagene autoleucel is under clinical development by Arcellx and currently in Phase III for Relapsed Multiple Myeloma. According to GlobalData, Phase III drugs for Relapsed Multiple Myeloma have ...

Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 31% phase ...

Multiple myeloma (also referred to as myeloma) is a type of rare, incurable cancer of the blood—also known as hematologic cancer. It affects cells called plasma cells, which are types of white blood ...

Ashraf Z. Badros, MB, ChB, discusses the results of the phase 3 AURIGA trial which evaluated daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

4 Over time, treatments have become more effective at reducing the disease burden of multiple myeloma, but challenges remain. Even when there is no detectable disease, relapse can occur years ...

Multiple myeloma causes changes in the blood cells that may lead to physical signs and symptoms. When you see your healthcare provider, they will probably ask about your symptoms and when they began.

In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory drugs achieved an overall response rate of 56.2% and median progression ...